Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 A

Eli Lilly and Company (NYSE:LLY) is one of the best stocks for beginners to buy now. On June 24, Eli Lilly completed its acquisition of Centessa Pharmaceuticals, aiming to advance the development of orexin receptor 2 agonists. This new class of medicine is designed to treat narcolepsy and other sleep-wake disorders by targeting the brain's natural systems for maintaining alertness and sleep stability.

Eli Lilly and Company (NYSE:LLY) plans to urgently utilize Centessa's clinical portfolio to address the profound and life-altering impacts of sleep disruption. By integrating these assets, the company seeks to explore the orexin system's broader potential for brain health and provide solutions for significant unmet needs in neuroscience.

This acquisition aligns with Eli Lilly's ongoing focus on pioneering life-changing discoveries across various health challenges, including diabetes, obesity, Alzheimer's, and immunology. The company remains committed to advancing innovative medical solutions and ensuring their accessibility for patients worldwide.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health,

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/eli-lilly-lly-acquires-centessa-080640313.html)